A Health Care Trio in Rally Mode
In the time I've been writing this column -- nearly two years -- various sub-industries from the medical sector have cycled in and out of leadership. When I ran some scans of heavy-volume gainers Tuesday morning, I saw several top-performing medical names making upside moves.
Shares of Jazz Pharmaceuticals (JAZZ), which makes treatments for psychiatric and neurological ailments including narcolepsy, anxiety and obsessive-compulsive disorder, are up nearly 17% this week to $56.24 on optimism about the outcome of a patent lawsuit pertaining to its narcolepsy drug Xyrem, which has been a solid grower. Tuesday's price action brought the stock to an all-time session high. I have to emphasize that it's never a good idea to chase a stock when it rallies to new highs. Instead, watch for a pullback to short- or medium-term moving averages....359 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.